Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Krystal Biotech (KRYS)

Krystal Biotech expects 2025 VYJUVEK revenue of $388 million to $389 million

Neutral Impact 3 of 5 earnings Written later

Krystal Biotech disclosed preliminary, unaudited 2025 results ahead of its J.P. Morgan Healthcare Conference presentation on January 12, 2026, including VYJUVEK net product revenue and cash of about $955 million as of December 31, 2025. It also gave 2026 combined non-GAAP R&D and SG&A expense guidance of $175 million to $195 million. The company said its audit is ongoing and the figures could change, with full 2025 results due in February 2026.

Key points

  • Preliminary Q4 2025 VYJUVEK net product revenue of $106 million to $107 million; full year 2025 of $388 million to $389 million
  • Cash, cash equivalents and investments of approximately $955 million as of December 31, 2025
  • 2026 combined non-GAAP R&D and SG&A expense guidance of $175 million to $195 million, excluding stock-based compensation
  • Figures are unaudited and subject to change; full 2025 results to be reported in February 2026

The filing

CompanyKrystal Biotech (KRYS)
Form8-K, current report
Filed with the SECJan 12, 2026, 7:50 AM ET
Accession number0001711279-26-000008

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.